Innoviva Inc

+0.12 (+0.87%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.02B
Current PE4.89
Forward PE 6.94
2yr Forward PE 10.17
See more stats
Estimates Current Quarter
Revenue$198.48 Million
Adjusted EPS$1.50
See more estimates
10-Day MA$14.38
50-Day MA$14.72
200-Day MA$16.78
See more pivots

Innoviva Inc Stock, NASDAQ:INVA

1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010
United States of America
Phone: +1.650.238.9600
Number of Employees: 5


Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.